Hangzhou Polymed Biopharmaceuticals
PrivateLast Round
VC Round
Dec 12, 2022
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Hangzhou Polymed Biopharmaceuticals is a biopharmaceutical company that focuses on the discovery and development of novel therapies for oncology and autoimmune diseases using protein degradation technologies and small molecule inhibitors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hangzhou Polymed Biopharmaceuticals Comparables
Compare Hangzhou Polymed Biopharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Gyre Therapeutics, Inc. | 77% | |
| C4 Therapeutics | 75% | |
| Arvinas Inc | 74% |
Hangzhou Polymed Biopharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Dec 12, 2022 | ||||
| VC Round | Jul 30, 2021 |
Hangzhou Polymed Biopharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cybernaut Investment Group | VC Round |
| ZJKF Capital Management | VC Round |
| MPC | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 117% MoM, reaching 3.1K.
- May 1, 2026
Grew 75% QoQ from 4 to 7 employees.
Hangzhou Polymed Biopharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Hangzhou Polymed Biopharmaceuticals's valuation, stock price, and market status.
Is Hangzhou Polymed Biopharmaceuticals a public or private company?
Hangzhou Polymed Biopharmaceuticals is a private company.
What is the current stock price of Hangzhou Polymed Biopharmaceuticals?
Hangzhou Polymed Biopharmaceuticals is a private company with no public stock price. No recent secondary market data is available.
How much is Hangzhou Polymed Biopharmaceuticals worth (valuation)?
Valuation information for Hangzhou Polymed Biopharmaceuticals is not publicly available.
Can I buy Hangzhou Polymed Biopharmaceuticals stock?
Hangzhou Polymed Biopharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Hangzhou Polymed Biopharmaceuticals's last funding round?
Hangzhou Polymed Biopharmaceuticals's most recent funding round was VC Round on December 12, 2022.
Who are the main investors in Hangzhou Polymed Biopharmaceuticals?
Key investors in Hangzhou Polymed Biopharmaceuticals include MPC.
Will Hangzhou Polymed Biopharmaceuticals IPO soon?
No public IPO plans have been announced for Hangzhou Polymed Biopharmaceuticals.
How can I track Hangzhou Polymed Biopharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Hangzhou Polymed Biopharmaceuticals's secondary market activity and sign up for updates.